Guo, H., Jin, C., Ding, L., Xie, J., Xu, J., Wang, R., . . . Zhou, S. De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review. Wolters Kluwer.
Chicago Style (17th ed.) CitationGuo, Hanxu, et al. De Novo Patients with High-volume Metastatic Hormone-sensitive Prostate Cancer Can Benefit from the Addition of Docetaxel to Triplet Therapy: Network-analysis and Systematic Review. Wolters Kluwer.
MLA (9th ed.) CitationGuo, Hanxu, et al. De Novo Patients with High-volume Metastatic Hormone-sensitive Prostate Cancer Can Benefit from the Addition of Docetaxel to Triplet Therapy: Network-analysis and Systematic Review. Wolters Kluwer.
Warning: These citations may not always be 100% accurate.